The mechanism of action of teprotumumab in patients with TED has not been fully characterized. Teprotumumab-trbw binds to IGF-1R and blocks its activation and signaling.

IGF-1R, insulin-like growth factor-1 receptor.

RAPID RESPONSE1,2

TEPEZZA decrease proptosis iconTEPEZZA decrease proptosis icon

Proptosis reduction at Week 6 in some patients continued through
Week 24*

PROVEN IN LOW DISEASE ACTIVITY
AND LONG DURATION TED3

Low-disease activity TED iconLow-disease activity TED icon

Significant proptosis reduction in randomized, double-masked, placebo-controlled study

OVER 15,000 PATIENTS TREATED1-5

TEPEZZA symptom alleviation iconTEPEZZA symptom alleviation icon

TEPEZZA has been shown to be effective in patients with a wide range of clinical manifestations

*In Phase 2 and 3 studies (N=83).1

In Phase 4 study (N=42).1,3

Help get your patient started on TEPEZZA now

Complete the PDF of the Patient Enrollment Form to get your patient started on TEPEZZA

COMPLETE THE PDF

COMPLETE THE PDF

Graphic showing TEPEZZA $0 Co-pay

Graphic showing TEPEZZA $0 Co-pay

Your patients may be
eligible for the Horizon
Commercial Co-pay Program

Subject to terms and conditions.

Hear how TEPEZZA has changed the way
Dr Kimberly Cockerham treats TED1

Preview of Dr. Kimberly Cockerman video
Read transcript

Hi I’m Kimberly Cockerham and I’m a board certified ophthalmologist with sub-specialty training in orbit, plastics and neuroophthalmology.

Thyroid Eye Disease is a vision-threatening, chronic disorder. Patients usually present with bulging of their eyes, redness, swelling, and complete disfigurement. They don’t feel good about how they look, they’re in pain. They’re angry, and frustrated. When somebody comes in and they’re experiencing these symptoms, what are they really going through?

It is very likely that a patient has seen multiple other practitioners with no results. I’ve had numerous patients who are approaching a decade or more of failed therapeutics. Now things are different.

Prior to January of 2020 when TEPEZZA was FDA approved as the first targeted treatment for Thyroid Eye Disease, there weren't a lot of options. Now I have TEPEZZA. It acts pretty quickly, and TEPEZZA makes the muscles behind the eye smaller. The redness and swelling go away. So, it's given me another tool in my tool chest.

Because of TEPEZZA, my conversations with my patients have changed for the better. I have a patient, and she gave me a picture of herself just before the Thyroid Eye Disease started. And then she showed me a picture of her in the midst of the disease, all alone, sad, frustrated. And then she sent me a picture just a couple of weeks after her last infusion, and her proptosis had improved, her eyes weren’t bulging, she was really looking much more like herself again, and there she was, with her son, her grandchild and just beaming.

Each patient’s Thyroid Eye Disease journey is different, but it’s really rewarding to be part of these patients’ lives. Now, with TEPEZZA, I can help impact that journey.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, weight decreased, nail disorders, and menstrual disorders.

Please see Full Prescribing Information for more information.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, weight decreased, nail disorders, and menstrual disorders.

Please see Full Prescribing Information for more information.

  1. TEPEZZA (teprotumumab-trbw) [prescribing information] Horizon.
  2. Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active Thyroid Eye Disease. N Engl J Med. 2020;382(4):341-352.
  3. Douglas RS, Couch S, Wester ST, et al. A randomized, quadruple-masked, placebo-controlled, multicenter trial to evaluate the efficacy and safety of teprotumumab in patients with chronic (inactive/low CAS) Thyroid Eye Disease. Presented at: ENDO 2023; June 15-18, 2023; Chicago, IL. Poster SAT-459.
  4. Douglas RS. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active Thyroid Eye Disease: a focus on proptosis. Eye (Lond). 2019;33(2):183-190.
  5. Data on File. Horizon, July 2023.